Abstract
BackgroundOnasemnogene abeparvovec (AVXS-101), a one-time intravenous gene-replacement therapy, treats the genetic root cause of spinal muscular atrophy (SMA). In the phase 1 study, AVXS-101 dramatically improved survival, motor function, and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have